Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

LESSONS LEARNED: Combination therapies in patients with hepatocellular carcinoma can be associated with overlapping toxicity and are therefore poorly tolerated. Using sorafenib at the maximum tolerated dose can lead to a higher incidence of toxicities. Consequently, combination studies might evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahda, Safi, Loehrer, Patrick J., Clark, Romnee S., Spittler, A. John, Althouse, Sandra K., Chiorean, E. Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912375/
https://www.ncbi.nlm.nih.gov/pubmed/27256874
http://dx.doi.org/10.1634/theoncologist.2016-0071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912375/
https://www.ncbi.nlm.nih.gov/pubmed/27256874
http://dx.doi.org/10.1634/theoncologist.2016-0071

Ejemplares similares